Breakthrough for baby with rare illness in world-first gene therapy trial
Fourteen-month-old Tomas was diagnosed with ornithine transcarbamylase (OTC) deficiency when he was a few weeks old ...
Hosted on MSN17d
iECURE gene therapy data suggests partial restoration of functional OTC
Gene editing company iECURE has said data from its Phase I/II ornithine transcarbamylase (OTC) deficiency trial could suggest partial restoration of functional OTC. New results from the company’s ...
MyChesCo on MSN13d
iECURE Highlights Promising Results from OTC-HOPE Study at 2025 ACMG Genetics Meeting
PHILADELPHIA, PA — iECURE, Inc. recently unveiled encouraging early data from its ongoing OTC-HOPE Phase 1/2 study at the ...
Nature25d
Chemical Structure of Bacterial Cell Walls: Ornithine and 2,4-Diaminobutyric Acid as Components of the Cell Walls of Plant Pathogenic Corynebacteria
Cummins, C. S., J. Gen. Microbiol., 28, 35 (1962).